iShares Nasdaq US Biotechnology UCITS ETF ISIN IE00BYXG2H39, WKN A2DWAW

 
 
 

Strategy of iShares Nasdaq US Biotechnology UCITS ETF

Investment strategy

The Nasdaq Biotechnology (Total Return) index tracks Nasdaq listed companies primarily engaged in biomedical research to develop new treatments and cures for human disease.

 

Nasdaq Biotechnology (1)

Equity (910) United States (159) Health Care (4)

Quote

EUR 4.07
XETRA
14/12/18
3.69 52 weeks low/high 4.71
52 weeks low/high
 
Savings plan ready
Show all offers
 

Risk and fees of iShares Nasdaq US Biotechnology UCITS ETF

Risk

EUR 16 m
Fund size
Fund size category

Replication

Physical (Optimized sampling)
Legal structure ETF
Strategy risk Long-only
Fund currency USD

Currency risk

Currency unhedged
Volatility 1 year (in EUR) 22.66% Risk category
Inception Date 19 October 2017
Maximum drawdown
since inception (in USD)
-3.61%
Maximum drawdown period 3 Months

Fees

0.35% p.a.
Total expense ratio
0.02% Compare 1.90%
Compare (Equity)

Dividend/ Taxes

Distribution policy Accumulating
Distribution frequency -
Fund domicile Ireland
Tax data Bundesanzeiger

Legal structure

Fund Structure Open-ended Investment Company (OEIC)
UCITS compliance Yes
Fund Provider iShares
Administrator State Street Fund Services (Ireland) Limited
Investment Advisor
Custodian Bank State Street Custodial Services (Ireland) Limited
Revision Company Deloitte
Fiscal Year End 31 May
Swiss representative BlackRock Asset Management Schweiz AG
Swiss paying agent State Street Bank International GmbH, Munich, Zurich Branch

Tax Status

Germany Tax transparent
Switzerland No ESTV Reporting
Austria Tax Reporting Fund
UK UK Reporting
EU Savings Directive -

Replication, swap, securities lending

Indextype Total return index
Swap counterparty
Collateral manager Bank of New York Mellon|Euroclear|State Street Bank|JP Morgan
Securities lending Yes
Securities lending counterparty UBS AG|Deutsche Bank AG|Goldman Sachs International|BNP Paribas Arbitrage SNC|Merrill Lynch International|Citigroup Inc|BNP Paribas SA|Societe Generale SA|JP Morgan Chase & Co|The Bank of Nova Scotia|HSBC Bank Plc|Nomura International Plc|Macquarie Bank Limited|Credit Suisse Securities (Europe) Ltd.|Barclays Bank Plc|J.P. Morgan Securities Plc|Citigroup Global Markets Ltd|Morgan Stanley & Co. International Plc|Skandinaviska Enskilda Banken AB|Barclays Capital Securities Ltd.
 
 
 

Performance of iShares Nasdaq US Biotechnology UCITS ETF

Return

1 year: 1.23%
Performance (incl. dividend)
Return in:
 
YTD 2017 2016 2015 2014
3.27% - - - -
1 month 3 months 6 months 1 year 3 years
-0.48% -9.87% -2.14% 1.23% -
 

Savings plan offers for the iShares Nasdaq US Biotechnology UCITS ETF

Select your savings amount:

 
Broker Rating Savings plan offer Brokerage fee More information
 
free of charge
free of charge
More info
 
EUR 1.50
1.50%
free of charge
More info
 
EUR 1.50
1.50%
free of charge
More info
Show all offers
 

Description of iShares Nasdaq US Biotechnology UCITS ETF

The iShares Nasdaq US Biotechnology UCITS ETF invests in stocks with focus Health Care, United States. The dividends in the fund are reinvested (accumulating).

The total expense ratio amounts to 0.35% p.a.. The fund replicates the performance of the underlying index by buying a selection of the most relevant index constituents (sampling technique). The iShares Nasdaq US Biotechnology UCITS ETF is a very small ETF with 16m Euro assets under management. The ETF is older than 1 year and is domiciled in Ireland.
 

Look for similar ETFs

 
— All quotes are 15 minutes delayed stock exchange quotes or NAVs (=daily published by fund provider). Quotes and reference data provided by Xignite, Inc., etfinfo and justETF GmbH. Returns include dividend payments. There is no warranty for completeness, accuracy and correctness for the displayed information.
Source:ETFinfo
 

Track your ETF strategies online